Valneva SE is a specialty vaccine company. It is focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. Valneva SE is based in Saint-Herblain, France.
| Revenue (Most Recent Fiscal Year) | $183.52M |
| Net Income (Most Recent Fiscal Year) | $-13.25M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 2.59 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.75 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 62.12 |
| Pre-Tax Margin (Trailing 12 Months) | -6.77% |
| Net Margin (Trailing 12 Months) | -43.08% |
| Return on Equity (Trailing 12 Months) | -43.05% |
| Return on Assets (Trailing 12 Months) | -16.23% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.70 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.12 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.92 |
| Inventory Turnover (Trailing 12 Months) | 1.88 |
| Book Value per Share (Most Recent Fiscal Quarter) | $2.41 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.13 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.17 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.19 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 85.09M |
| Free Float | 72.41M |
| Market Capitalization | $516.52M |
| Average Volume (Last 20 Days) | 0.01M |
| Beta (Past 60 Months) | 1.74 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 14.91% |
| Percentage Held By Institutions (Latest 13F Reports) | 11.39% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |